Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Zentalis Pharmaceuticals Inc shares valued at $28,294 were purchased by Diana Hausman on Oct 31 ’24. At $2.86 per share, Diana Hausman acquired 9,888 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Vultaggio Vincent sold 1,603 shares, netting a total of over 5,098 in proceeds. Following the sale of shares at $3.18 each, the insider now holds 33,855 shares.
Before that, Gallagher Cam had sold 9,597 shares from its account. In a trade valued at $114,972, the President, Interim CFO traded Zentalis Pharmaceuticals Inc shares for $11.98 each. Upon closing the transaction, the insider’s holdings decreased to 9,597 shares, worth approximately $1.84 million.
As published in a research note from Wedbush on August 12, 2024, Zentalis Pharmaceuticals Inc [ZNTL] has been rated up from an Underperform to a Neutral and the price target has been revised to $4. Analysts at UBS downgraded the stock from ‘”a Buy”‘ to ‘”a Neutral”‘ outlook in a report released in mid June. As of June 18, 2024, Wells Fargo has decreased its “an Overweight” rating to a “an Equal weight” for ZNTL. Earlier on June 18, 2024, Wedbush downgraded its rating. Their new recommendation was “an Underperform” for ZNTL stock which previously was a “a Neutral”.
Analyzing ZNTL Stock Performance
During the last five days, there has been a drop of approximately -16.71%. Over the course of the year, Zentalis Pharmaceuticals Inc shares have dropped approximately -80.76%. Shares of the company reached a 52-week high of $18.07 on 02/28/24 and a 52-week low of $2.66 on 10/31/24. A 50-day SMA is recorded $3.31, while a 200-day SMA reached $6.83. Nevertheless, trading volume fell to 1.47 million shares from 1.93 million shares the previous day.
Support And Resistance Levels for Zentalis Pharmaceuticals Inc (ZNTL)
According to the 24-hour chart, there is a support level at 2.74, which, if violated, would cause prices to drop to 2.57. In the upper region, resistance lies at 3.15. The next price resistance is at 3.39. RSI (Relative Strength Index) is 38.88 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.32, which suggests the price will decrease in the coming days. Percent R is at 91.18%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
